Hexadecyldimethylamine (HDMA) is a cationic surfactant commonly used in various industrial and consumer applications. It is synthesized through the reaction of hexadecyl alcohol with dimethylamine in the presence of a catalyst. HDMA exhibits antimicrobial properties, particularly against bacteria and fungi, making it effective as an antiseptic and disinfectant. Its amphiphilic nature allows it to interact with both hydrophobic and hydrophilic environments, enabling its use as an emulsifier, wetting agent, and foam stabilizer in formulations like detergents, cosmetics, and pharmaceuticals. The study of HDMA focuses on its potential applications in areas such as drug delivery, bioremediation, and wastewater treatment due to its surfactant properties and antimicrobial activity.'
hexadecyldimethylamine: has antifungal activity; isolated from Arthrobacter agilis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 16221 |
| CHEMBL ID | 1877748 |
| SCHEMBL ID | 108224 |
| MeSH ID | M000595518 |
| Synonym |
|---|
| AKOS005451209 |
| n,n-dimethyl-n-hexadecylamine |
| n,n-dimethylhexadecylamine |
| nsc-8493 |
| armeen dm 16d |
| hexadecylamine,n-dimethyl- |
| n,n-dimethylcetylamine |
| 1-hexadecanamine,n-dimethyl- |
| 112-69-6 |
| hexadecyldimethylamine |
| dimethylcetylamine |
| cetyldimethylamine |
| nsc8493 |
| dimethylhexadecylamine |
| palmityl dimethyl amine |
| dimethyl-n-hexadecylamine |
| n,n-dimethylhexadecan-1-amine |
| nsc 404177 |
| n,n-dimethyl-1-hexadecylamine |
| hexadecylamine, n,n-dimethyl- |
| brn 1755921 |
| palmityldimethylamine |
| n,n-dimethyl-1-hexadecanamine |
| bairdcat b16 |
| dimethyl palmitamine |
| einecs 203-997-2 |
| ipl 67 |
| ai3-16727 |
| dimethylpalmitylamine |
| n,n-dimethylpalmitylamine |
| dimethyl palmitylamine |
| farmin dm 60 |
| armeen dm16d |
| n-hexadecyldimethylamine |
| genamin 16r302d |
| 1-hexadecanamine, n,n-dimethyl- |
| nsc-404177 |
| nsc404177 |
| NCGC00164287-01 |
| 68439-70-3 |
| STK382562 |
| n,n-dimethylhexadecylamine, technical, >=95% (gc) |
| FT-0655250 |
| D1568 |
| 1-(dimethylamino)hexadecane |
| A802633 |
| 75444-69-8 |
| cas-112-69-6 |
| tox21_202994 |
| dtxsid9026924 , |
| NCGC00260539-01 |
| dtxcid606924 |
| 5e4qi660pw , |
| ec 203-997-2 |
| unii-5e4qi660pw |
| einecs 268-217-5 |
| ec 268-220-1 |
| 68037-96-7 |
| einecs 268-220-1 |
| 68037-93-4 |
| einecs 270-414-6 |
| ec 270-414-6 |
| dimethyl palmitamine [inci] |
| AB01333971-02 |
| SCHEMBL108224 |
| dimethyl-1-hexadecanamine |
| adma 16 amine |
| n,n-dimethyl hexadecyl amine |
| dimethylmono-n-hexadecylamine |
| dimethyl-cetylamine |
| hexadecyl dimethyl amine |
| dimethyl hexadecyl amine |
| dimethyl-hexadecylamine |
| n-hexadecyl-n,n-dimethylamine |
| CHEMBL1877748 |
| J-002819 |
| mfcd00015086 |
| E75842 |
| Q24736646 |
| DTXSID801022423 , |
| FT-0776014 |
| hexadecyl dimethylamine |
| di-methyl behenylamine |
| n-dimethylhexadecylamine |
| NCGC00164287-02 |
| CS-0152196 |
| AS-80934 |
| EN300-33506 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 1.3870 | 0.3758 | 27.4851 | 61.6524 | AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 2.4450 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 0.0098 | 0.0010 | 24.5048 | 61.6448 | AID743212 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 7.9433 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.00) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||